Aurora Cannabis (ACB) Income from Discontinued Operations (2020 - 2026)
Aurora Cannabis (ACB) posted quarterly Income from Discontinued Operations of 56015393.64 for Q1 2026, down 615.22% year-over-year from 10872201.18 in Q1 2025, and down 48722.05% quarter-over-quarter from 114733.81 in Q4 2025.
Aurora Cannabis (ACB) Income from Discontinued Operations (2020 - 2026) Analysis & Trends
Aurora Cannabis (ACB) has reported Income from Discontinued Operations for 7 consecutive years, with 56015393.64 the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Discontinued Operations fell 615.22% year-over-year to 56015393.64; the TTM figure through Mar 2026 stood at 56395146.63 (down 208.86% YoY), while the FY2026 annual figure was 56400414.24, down 207.96% from the prior year.
- Income from Discontinued Operations slipped to 56015393.64 in Q1 2026 per ACB's latest filing, from 114733.81 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 222266.73 in Q2 2024 and bottomed at 56015393.64 in Q1 2026.
- Historically, Income from Discontinued Operations has averaged 7360325.25 across 5 years, with a median of 1406995.57 in 2024.
- Annual changes were most pronounced in 2022 — Income from Discontinued Operations tumbled 883.35% — and 2024, when it jumped 132.49%.
- Aurora Cannabis' Income from Discontinued Operations stood at 13350530.68 in 2022, then soared by 98.1% to 253414.76 in 2023, then surged by 132.49% to 82322.65 in 2024, then slumped by 239.37% to 114733.81 in 2025, then slumped by 48722.05% to 56015393.64 in 2026.
- Business Quant data shows ACB's Income from Discontinued Operations at 56015393.64 in Q1 2026, 114733.81 in Q4 2025, and 84289.66 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.05 Bn | 43.08 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.39 Bn | 39.74 Bn | 2.15 Bn | - |
| 3 | Zoetis | 31.86 Bn | 30.18 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.78 Bn | 22.99 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 22.25 Bn | 19.59 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.58 Bn | 15.19 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 11.92 Bn | 11.39 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.16 Bn | 9.99 Bn | - | - |
| 10 | Aurora Cannabis | 233.15 Mn | 160.83 Mn | 25.75 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -56.02 Mn |
| Dec 31, 2025 | -114,733.81 |
| Sep 30, 2025 | 84,289.66 |
| Jun 30, 2025 | -349,308.85 |
| Mar 31, 2025 | -7.83 Mn |
| Dec 31, 2024 | 82,322.65 |
| Sep 30, 2024 | -10.73 Mn |
| Jun 30, 2024 | 222,266.73 |
| Mar 31, 2024 | -1.44 Mn |
| Dec 31, 2023 | -253,414.76 |
| Sep 30, 2023 | -1.78 Mn |
| Dec 31, 2022 | -13.35 Mn |
| Sep 30, 2022 | -10.19 Mn |
| Jun 30, 2022 | -1.38 Mn |
| Jun 30, 2021 | 175,721.87 |
| Sep 30, 2020 | -1.37 Mn |